D
David Spiegel
Researcher at Stanford University
Publications - 838
Citations - 50967
David Spiegel is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 106, co-authored 733 publications receiving 46276 citations. Previous affiliations of David Spiegel include Tel Aviv University & University of Adelaide.
Papers
More filters
Journal ArticleDOI
The treatment of contractures of the hand using self-hypnosis.
David Spiegel,Robert A. Chase +1 more
TL;DR: The successful treatment of a man with severe posttraumatic contractures of the hand using a combined psychological and physical rehabilitation approach and hypnosis can facilitate recovery in such psychosomatic disorders in patients with the requisite hypnotic capacity and motivation is reported.
Journal ArticleDOI
Grand challenge commentary: Synthetic immunology to engineer human immunity.
TL;DR: Rationally designing new strategies to control the human immune response stands as a key challenge for the scientific community and chemical biologists have the opportunity to address specific issues.
Journal ArticleDOI
Disengagement and social support moderate distress among women with a family history of breast cancer.
TL;DR: An association between distress and disengagement is similar to that found in metastatic breast cancer patients themselves, and the findings suggest a subgroup that merits and might respond to more intensive intervention to provide support and facilitate emotional expression.
Journal ArticleDOI
Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer.
Mark M. Awad,Ramaswamy Govindan,Kristen N. Balogh,David Spiegel,Edward B. Garon,Meghan E. Bushway,Asaf Poran,Joong Hyuk Sheen,Victoria Kohler,Ekaterina Esaulova,John Srouji,Suchitra Ramesh,Rohit Vyasamneni,Binisha Karki,Tracey E. Sciuto,H. Sethi,Jesse Z. Dong,Melissa A. Moles,Kelledy Manson,Michael S. Rooney,Zakaria S. Khondker,Mark DeMario,Richard B. Gaynor,Lakshmi Srinivasan +23 more
TL;DR: In this paper , the authors reported the clinical and immune data from a Phase Ib clinical trial of a personalized neoantigen-vaccine NEO-PV-01 in combination with pemetrexed, carboplatin, and pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC).